Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H39O4.Na |
Molecular Weight | 414.5547 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]([H])(CCC(=O)[O-])[C@@]1([H])CC[C@@]2([H])[C@@]3([H])[C@]([H])(CC[C@]12C)[C@@]4(C)CC[C@]([H])(C[C@@]4([H])C[C@@]3([H])O)O.[Na+]
InChI
InChIKey=WDFRNBJHDMUMBL-OICFXQLMSA-M
InChI=1S/C24H40O4.Na/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26;/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28);/q;+1/p-1/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-;/m1./s1
Molecular Formula | C24H39O4 |
Molecular Weight | 391.565 |
Charge | -1 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a3a8942-94d4-4292-bf74-0a67d92acb90#section-11.1https://www.drugs.com/pro/chenodiol.html | https://www.drugbank.ca/drugs/DB06777Curator's Comment:: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB01586
Sources: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a3a8942-94d4-4292-bf74-0a67d92acb90#section-11.1https://www.drugs.com/pro/chenodiol.html | https://www.drugbank.ca/drugs/DB06777
Curator's Comment:: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB01586
Chenodiol is the non-proprietary name for chenodeoxycholic acid, a naturally occurring human bile acid. It is a bitter-tasting white powder consisting of crystalline and amorphous particles freely soluble in methanol, acetone and acetic acid and practically insoluble in water. Chenodiol suppresses hepatic synthesis of both cholesterol and cholic acid, gradually replacing the latter and its metabolite, deoxycholic acid in an expanded bile acid pool. These actions contribute to biliary cholesterol desaturation and gradual dissolution of radiolucent cholesterol gallstones in the presence of a gall-bladder visualized by oral cholecystography. Bile acids may also bind the the bile acid receptor (FXR) which regulates the synthesis and transport of bile acids. Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2047 Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=22223860 |
|||
10.0 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Chenodiol Approved UseChenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment. Launch Date4.28198396E11 |
|||
Primary | URSODIOL Approved UseUrsodiol Launch Date6.1655037E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.2 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22414767 |
15 mg/kg bw 1 times / day multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
URSODIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
49.8 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22414767 |
15 mg/kg bw 1 times / day multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
URSODIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg/kg 3 times / day multiple, oral (total daily dose) Highest studied dose Dose: 50 mg/kg, 3 times / day Route: oral Route: multiple Dose: 50 mg/kg, 3 times / day Sources: Page: p.18 |
unhealthy, 37-65 n = 7 Health Status: unhealthy Condition: Amyotrophic lateral sclerosis Age Group: 37-65 Sex: M+F Population Size: 7 Sources: Page: p.18 |
|
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: Page: p.4 |
unhealthy n = 60 Health Status: unhealthy Condition: Primary biliary cirrhosis Population Size: 60 Sources: Page: p.4 |
Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea (1.7%) Sources: Page: p.4 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | 1.7% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: Page: p.4 |
unhealthy n = 60 Health Status: unhealthy Condition: Primary biliary cirrhosis Population Size: 60 Sources: Page: p.4 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [Inhibition 20 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/16678547/ |
yes | no (co-administration study) Comment: UDCA did not lead to detectable changes in midazolam pharmacokinetics Sources: https://pubmed.ncbi.nlm.nih.gov/16678547/ |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/16678547/ |
yes | weak (co-administration study) Comment: UDCA modestly decreased digoxin disposition without Sources: https://pubmed.ncbi.nlm.nih.gov/16678547/ |
PubMed
Title | Date | PubMed |
---|---|---|
[Ursodeoxycholic acid as the main treatment of hepatobiliary diseases in children and teenagers]. | 2001 |
|
Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid. | 2001 |
|
Ursodeoxycholic acid for the treatment of intrahepatic cholestasis of pregnancy. | 2001 Apr |
|
Primary biliary cirrhosis: from induction to destruction. | 2001 Apr |
|
Genetic disorders and molecular mechanisms in cholestatic liver disease--a clinical approach. | 2001 Apr |
|
Drug-induced cholestasis. | 2001 Apr |
|
Prevention of colon cancer with ursodiol in ulcerative colitis. | 2001 Aug |
|
Lichenoid eruptions due to ursodeoxycholic acid administration. | 2001 Aug |
|
Ursodiol prevents UC-associated CRC. | 2001 Aug |
|
Ursodeoxycholic acid causing exacerbation of dermatitis herpetiformis. | 2001 Aug |
|
Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. | 2001 Aug |
|
Stimulation of ATP secretion in the liver by therapeutic bile acids. | 2001 Aug 15 |
|
Micronuclei induction, cell cycle delay and apoptosis as markers of cellular stress caused by ursodeoxycholic acid in human lymphocytes. | 2001 Aug 22 |
|
Crystal structure of human type III 3alpha-hydroxysteroid dehydrogenase/bile acid binding protein complexed with NADP(+) and ursodeoxycholate. | 2001 Aug 28 |
|
Effect of bile acids on formation of azoxymethane-induced aberrant crypt foci in colostomized F344 rat colon. | 2001 Aug 28 |
|
Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. | 2001 Dec 14 |
|
Treatment of primary biliary cirrhosis. | 2001 Jan-Dec |
|
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. | 2001 Jul |
|
Fetal bile acid metabolism: analysis of urinary 3beta-monohydroxy-delta(5) bile acid in preterm infants. | 2001 Jul |
|
Rapid progress of acute suppurative cholangitis to secondary sclerosing cholangitis sequentially followed-up by endoscopic retrograde cholangiography. | 2001 Jul |
|
A case of autoimmune hepatitis with a high titer of antimitochondrial antibody and normal gamma-globulinemia. | 2001 Jul |
|
Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. | 2001 Jul |
|
Prevention and treatment of veno-occlusive disease. | 2001 Jul-Aug |
|
Effect of bile acids on the proliferative activity and apoptosis of rat hepatocytes. | 2001 Jun |
|
Effect of ursodeoxycholate in University of Wisconsin solution on long term preservation of rat livers. | 2001 Jun |
|
Ofloxacin and ursodeoxycholic acid versus ursodeoxycholic acid alone to prevent occlusion of biliary stents: a prospective, randomized trial. | 2001 Jun |
|
Effect of bezafibrate in primary biliary cirrhosis: a pilot study. | 2001 Jun |
|
Effect of bile salts on colonic mucus secretion in isolated vascularly perfused rat colon. | 2001 Jun |
|
Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. | 2001 Jun |
|
Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation. | 2001 Jun |
|
Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. | 2001 Jun |
|
Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. | 2001 Jun 1 |
|
[Effects of bile acid preparations on DNA biosynthesis, apoptosis, and necrosis in hepatocytes in vitro]. | 2001 Mar-Apr |
|
Enhancement of endothelial nitric oxide production by chenodeoxycholic acids in patients with hepatobiliary diseases. | 2001 May |
|
Synthetic bile acid derivatives induce nonapoptotic death of human retinal pigment epithelial cells. | 2001 May |
|
Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future? | 2001 May |
|
Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate. | 2001 May |
|
Autoimmune liver disease. Current standards, future directions. | 2001 May |
|
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. | 2001 May |
|
Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis. | 2001 May |
|
[Correction of metabolic disturbances in patients with cholestasis]. | 2001 May-Jun |
|
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. | 2001 Oct |
|
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. | 2001 Oct 19 |
|
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. | 2001 Oct 19 |
|
The natural history of primary biliary cirrhosis: of genes and cooperation. | 2001 Sep |
|
Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? | 2001 Sep |
|
Ursodeoxycholic acid and in vitro vasoactivity of hydrophobic bile acids. | 2001 Sep |
|
Geranylgeraniol, an intermediate product in mevalonate pathway, induces apoptotic cell death in human hepatoma cells: death receptor-independent activation of caspase-8 with down-regulation of Bcl-xL expression. | 2001 Sep |
|
Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. | 2001 Sep |
|
Biliary excretion of tauroursodeoxycholate-3-sulfate in the rat. | 2001 Sep |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 22:06:06 UTC 2021
by
admin
on
Fri Jun 25 22:06:06 UTC 2021
|
Record UNII |
6V4571KSKE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66913
Created by
admin on Fri Jun 25 22:06:06 UTC 2021 , Edited by admin on Fri Jun 25 22:06:06 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6V4571KSKE
Created by
admin on Fri Jun 25 22:06:06 UTC 2021 , Edited by admin on Fri Jun 25 22:06:06 UTC 2021
|
PRIMARY | |||
|
C91034
Created by
admin on Fri Jun 25 22:06:06 UTC 2021 , Edited by admin on Fri Jun 25 22:06:06 UTC 2021
|
PRIMARY | |||
|
2646-38-0
Created by
admin on Fri Jun 25 22:06:06 UTC 2021 , Edited by admin on Fri Jun 25 22:06:06 UTC 2021
|
PRIMARY | |||
|
23696998
Created by
admin on Fri Jun 25 22:06:06 UTC 2021 , Edited by admin on Fri Jun 25 22:06:06 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |